Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of BMS-986165 Solid Dispersion Formulations in Healthy Subjects
NCT04065932Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of deucravacitinib in systemic lupus erythematosus (SLE) (6 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration at Day 1, Area under the serum concentration-time curve from time zero to time of last quantifiable concentration at Day 1 and 1 more. Started Aug 2019; status: completed.
02
Drugs
deucravacitinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT04065932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04065932.